Behavioural and cognitive phenotypes in children with neurofibromatosis type 1 (NF1): The link with the neurobiological level

Brain and Development

Volumn 33, Issue 1, 2011, Pages 52-61

  Hachon, Caroline ^a,b   Iannuzzi, Stéphanie ^a,b   Chaix, Yves ^a,b,c  

^a HÔPITAL DES ENFANTS   (France)

^b CHU PURPAN   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Brain imagery; Child; Cognitive impairment; NF1; Reading disabilities

Indexed keywords

METHYLPHENIDATE; MEVINOLIN; PLACEBO;

ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; COGNITIVE DEFECT; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMAN; HYPERCHOLESTEROLEMIA; LEARNING DISORDER; MACROCEPHALY; MENTAL DEFICIENCY; NEUROFIBROMATOSIS; NEUROFIBROMATOSIS TYPE 1; NEUROIMAGING; NONHUMAN; ORIENTING RESPONSE; PHENOTYPE; RECOGNITION; REVIEW; VISUOMOTOR COORDINATION;

ANIMALS; BEHAVIOR; COGNITION; COGNITION DISORDERS; DYSLEXIA; HUMANS; LEARNING DISORDERS; NEUROFIBROMATOSIS 1; NEUROPSYCHOLOGICAL TESTS; PHENOTYPE;

EID: 78650306177     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2009.12.008     Document Type: Review

References (61)

1. Kayl A.E., Moore B.D. Behavioral phenotype of neurofibromatosis type 1. Ment Retard Dev Disabil Res Rev 2000, 6:117-124.
2. Johnston M.V. Brain plasticity in pediatric neurology. Eur J Paediatr Neurol 2003, 7:105-113.
3. Johnston M.V. Clinical disorders of brain plasticity. Brain Dev 2004, 26:73-80.
4. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Conference. Arch Neurol 1988; 45: 575-8.
5. Ozonoff S. Cognitive impairment in neurofibromatosis type 1. Am J Med Genet 1999, 89:45-52.
6. North K. Neurofibromatosis type 1. Am J Med Genet 2000, 97:119-127.
7. Hyman S.L., Shores A., North K.N. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 2005, 65:1037-1044.
8. Frith U., Morton J., Leslie A.M. The cognitive basis of a biological disorder: autism. Trends Neurosci 1991, 14:433-437.
9. Hyman S.L., Shores A., North K.N. Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol 2006, 48:973-977.
10. Descheemaeker M.J., Ghesquière P., Symons H., Fryns J.P., Legius E. Behavioural, academic and neuropsychological profile of normally gifted neurofibromatosis type 1 children. J Intellect Disabil Res 2005, 49:33-46.
11. Coudé F.X., Mignot C., Lyonnet S., Munnich A. Academic impairment is the most frequent complication of neurofibromatosis type-1(NF1) in children. Behav Genet 2006, 36:660-664.
12. Billingsley R.L., Jackson E.F., Slopis J.M., Swank P.R., Manhankali S., Moore B.D. Functional magnetic resonance imaging of phonologic processing in neurofibromatosis 1. J Child Neurol 2003, 18:732-740.
13. Clements-Stephens A.M., Rimrodt S.L., Gaur P., Cutting L.E. Visuospatial processing in children with neurofibromatosis type 1. Neuropsychologia 2008, 46:690-697.
14. North K., Joy P., Yuille D., Cocks N., Mobbs E., Hutchins P., et al. Specific learning disability in children with neurofibromatosis type 1: significance of MRI abnormalities. Neurology 1994, 44:878-883.
15. Eliason M.J. Neurofibromatosis: implications for learning and behavior. J Dev Behav Pediatr 1986, 7:175-179.
16. Eliason M.J. Neuropsychological patterns: neurofibromatosis compared to developmental learning disorders. Neurofibromatosis 1988, 1:17-25.
17. Hofman K.J., Harris E.L., Bryan R.N., Denckla M.B. Neurofibromatosis type 1: the cognitive phenotype. J Pediatr 1994, 124:S1-S8.
18. Cutting L.E., Koth C.W., Denckla M.B. How children with neurofibromatosis type 1 differ from " typical" learning disabled clinic attenders: nonverbal learning disabilities revisited. Dev Neuropsychol 2000, 17:29-47.
19. Cutting L.E., Koth C.W., David D., Denckla M.B. Comparison of neuropsychological profiles of children with NF-1 and RD. J Int Neuropsychol Soc 2003, 9:203.
20. Billingsley R.L., Slopis J.M., Swank P.R., Jackson E.F., Moore B.D. Cortical morphology associated with language function in neurofibromatosis, type I. Brain Lang 2003, 85:125-139.
21. Watt S.E., Shores A., North K.N. An examination of lexical and sub-lexical reading skills in children with neurofibromatosis type 1. Child Neuropsychol 2008, 14:401-418.
22. Mazzocco M.M. Math learning disability and math LD subtypes: evidence from studies of Turner syndrome, fragile X syndrome, and neurofibromatosis type 1. J Learn Disabil 2001, 34:520-533.
23. Levine T.M., Materek A., Abel J., O'Donnell M., Cutting L.E. Cognitive profile of neurofibromatosis type 1. Semin Pediatr Neurol 2006, 13:6-20.
24. North K., Hyman S., Barton B. Cognitive deficits in neurofibromatosis 1. J Child Neurol 2002, 17:605-612.
25. Koth C.W., Cutting L.E., Denckla M.B. The association of neurofibromatosis type 1 and attention deficit hyperactivity disorder. Child Neuropsychol 2000, 6:185-194.
26. Chaix Y., Albaret J.M., Brassard C., Cheuret E., de Castelnau P., Benesteau J., et al. Motor impairment in dyslexia: the influence of attention disorders. Eur J Paediatr Neurol 2007, 11:368-374.
27. Noll R.B., Reiter-Purtill J., Moore B.D., Schorry E.K., Lovell A.M., Vannatta K., et al. Social, emotional, and behavioral functioning of children with NF1. Am J Med Genet A 2007, 143A:2261-2273.
28. Mautner F.V., Kluwe L., Thakker S.D., Leark R.A. Treatment of ADHD in neurofibromatosis type 1. Dev Med Child Neurol 2002, 44:164-170.
29. Kayl A.E., Moore B.D. Behavioral phenotype of neurofibromatosis, type 1. Ment Retard Dev Disabil Res Rev 2000, 6:117-124.
30. Johnson H., Wiggs L., Stores G., Huson S.M. Psychological disturbance and sleep disorders in children with neurofibromatosis type 1. Dev Med Child Neurol 2005, 47:237-242.
31. Sebold C.D., Lovell A., Hopkin R., Noll R., Schorry E. Perception of disease severity in adolescents diagnosed with neurofibromatosis type 1. J Adolesc Health 2004, 35:297-302.
32. Schrimsher G.W., Billingsley R.L., Slopis J.M., Moore B.D. Visual-spatial performance deficits in children with neurofibromatosis type-1. Am J Med Genet A 2003, 120:326-330.
33. Dilts C.V., Carey J.C., Hofman R.O., Creel D., Ward K., Clark E., et al. Children and adolescents with neurofibromatosis 1: a behavioral phenotype. J Dev Behav Pediat 1996, 17:229-239.
34. Joy P., Roberts C., North K., de Silva M. Neuropsychological function and MRI abnormalities in neurofibromatosis type 1. Dev Med Child Neurol 1995, 37:906-914.
35. Mazzocco M.M., Turner J.E., Denckla M.B., Hofman K.J., Scanlon D.C., Vellutino F.R. Language and reading deficits associated with NF1: evidence for not-so-nonverbal learning disability. Dev Neurosci 1995, 11:503-522.
36. Stanovich K.E., Siegel L.S. Phenotypic performance profile of children with reading disabilities. A regression-based test of the phonological-core variable-difference model. J Educ Psychol 1994, 86:24-53.
37. Denckla M.B. Neurofibromatosis type 1: a model for the pathogenesis of reading disabilities. Ment Retard Dev Disabil Res Rev 1996, 2:48-53.
38. Cutting L.E., Clements A.M., Lightman A.D., Yerby-Hammack P.D., Denckla M.B. Cognitive profile of neurofibromatosis type 1: rethinking nonverbal learning disabilities. Learn Disabilities Res Practice 2004, 19:155-165.
39. Coltheart M. Analysing developmental disorders of reading. Adv Speech Lang Pathol 2005, 7:49-57.
40. Steen R.G., Taylor J.S., Langston J.W., Glass J.O., Brewer V.R., Reddick W.E., et al. Prospective evaluation of the brain in asymptomatic children with neurofibromatosis type 1: relationship of macrocephaly to T1 relaxation changes and structural brain abnormalities. Am J Neuroradiol 2001, 22:810-817.
41. Greenwood R.S., Tupler L.A., Whitt K., Buu A., Dombeck C.B., Harp A.G., et al. Brain morphometry, T2-weighted hyperintensities and IQ in children with neurofibromatosis type 1. Arch Neurol 2005, 62:1904-1908.
42. Cutting L.E., Cooper K.L., Koth C.W., Mostofsky S.H., Kates W.R., Denckla M.B., et al. Megalencephaly in NF1. Predominantly white matter contribution and mitigation by ADHD. Neurology 2002, 59:1388-1394.
43. Billingsley R.L., Schrimsher G.W., Jackson E.F., Slopis J.M., Moore B.D. Significance of planum temporale and planum parietale morphologic features in neurofibromatosis 1. Arch Neurol 2002, 59:616-622.
44. Hyman S.L., Gill D.S., Shores E.A., Steinberg A., North Kathryn T2-Hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning. J Neurol Neurosurg Psychiatry 2007, 78:1088-1091.
45. Lopes Ferraz Filho J.R., Munis M.P., Soares Souza A., Sanches R.A., Goloni-Bertollo E.M., Pavarino-Bertelli E.C. Unidentified bright objects on brain MRI in children as a diagnostic criterion for neurofibromatosis type 1. Pediatr Radiol 2008, 38:305-310.
46. Moore B.D., Slopis J.M., Schomer D., Jackson E.F., Levy B.M. Neuropsychological significance of areas of high signal intensity on brain MRIs of children with neurofibromatosis. Neurology 1996, 46:1660-1668.
47. Legius E., Descheemaeker M.J., Steyaert J., et al. Neurofibromatosis type 1 in childhood: correlation of MRI findings with intelligence. J Neurol Neurosurg Psychiatry 1995, 59:638-640.
48. DiPaolo D.P., Zimmerman R.A., Rorke L.B., Zackai E.H., Bilniuk L.H., Yachmis A.T. Neurofibromatosis type 1: pathologic substrate of high signal intensity foci in the brain. Neuroradiology 1995, 195:721-724.
49. Tognini G., Ferrozzi F., Garlaschi G., Piazza P., Patti A., Virdis R., et al. Brain apparent diffusion coefficient evaluation in pediatric patients with neurofibromatosis type 1. J Comput Assist Tomogr 2005, 29:298-304.
50. van Engelen S.J., Krab L.C., Moll H.A., de Goede-Bolder A., Pluijm S.M., Catsman-Berrevoets C.E., et al. Quantitative differentiation between healthy and disordered brain matter in patients with neurofibromatosis type I using diffusion tensor imaging. Am J Neuroradiol 2008, 29:816-822.
51. Hyman S.L., Gill D.S., Shores E.A., Steinberg A., Joy P., Gibikote S.V., et al. Natural history of cognitive deficits and their relationship to MRI T2-hyperintensities in NF1. Neurology 2003, 60:1139-1145.
52. Gill D.S., Hyman S.L., Steinberg A., North K.N. Age-related findings on MRI in neurofibromatosis type 1. Pediatr Radiol 2006, 36:1048-1056.
53. Mott S.H., Mazzocco M., Hofman K., Melhem H., Reiss A.L., Denckla M.B. Neurofibromatosis type 1: correlation between volumes of T2-weighted high-intensity signals (UBOs) within neural pathways and impaired performance on judgement of line orientation. Ann Neurol 1995, 38:509.
54. Goh W.H., Khong P.L., Leung C.S., Wong V.C. T2-weighted hyperintensities (unidentified bright objects) in children with neurofibromatosis 1: their impact on cognitive function. J Child Neurol 2004, 19:853-858.
55. Kaplan A.M., Chen K., Lawson M.A., Wodrich D.L., Bonstelle C.T., Reiman E.M. Positron emission tomography in children with neurofibromatosis type 1. J Child Neurol 1997, 12:499-506.
56. Wang P.Y., Kaufmann W.E., Koth C.W., Denckla M.B., Barker P.B. Thalamic involvement in neurofibromatosis type 1: evaluation with proton magnetic resonance spectroscopic imaging. Ann Neurol 2000, 47:477-484.
57. Billingsley R.L., Jackson E.F., Slopis J.M., Swank P.R., Manhankali S., Moore B.D. Functional MRI of visual-spatial processing in neurofibromatosis type 1. Neuropsychologia 2004, 42:395-404.
58. Costa R.M., Silva A.J. Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1. J Child Neurol 2002, 17:622-626.
59. Costa R.M., Federov N.B., Kogan J.H., Murphy G.G., Stern J., Ohno M., et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 2002, 415:526-5230.
60. Li W., Cui Y., Kushner S.A., Brown R.A., Jentsch J.D., Frankland P.W., et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 2005, 15:1961-1967.
61. Krab L.C., de Goede-Bolder A., Aarsen F.K., Pluijm S.M., Bouman M.J., van der Geest J.N., et al. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA 2008, 300:287-294.